Acurx Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

NATURE OF OPERATIONS (Details)

NATURE OF OPERATIONS (Details) - USD ($)									1 Months Ended	6 Months Ended
NATURE OF OPERATIONS (Details) - USD ($)	Jun. 17, 2025	May 08, 2025	Mar. 06, 2025	Jan. 06, 2025	Nov. 15, 2023	May 18, 2023	Jul. 27, 2022	Jun. 29, 2021	Feb. 28, 2018	Jun. 30, 2024	Jun. 30, 2025	Dec. 31, 2024
Common stock, Par value											$ 0.001	$ 0.001
Cash											$ 6,064,128	$ 3,706,713
IPO
Shares issued (in shares)								143,750
Proceeds from stock issue								$ 17,300,000
Share price (in dollars per share)								$ 120
At the Market Offering
Shares issued (in shares)										62,743
Shares issued to date (in shares)				141,516
Proceeds from stock issue										$ 4,800,000
Proceeds from stock issuance to date				$ 9,200,000
Share price (in dollars per share)										$ 76
Aggregate offering price					$ 17,000,000
Registered Direct Offering
Proceeds from stock issue						$ 4,000,000	$ 4,200,000
Registered Direct Offering \| Pre-funded warrants
Shares issued (in shares)						36,574	6,538
Registered Direct Offering \| Series A warrants
Shares issued (in shares)							64,499
Registered Direct Offering \| Series B warrants
Shares issued (in shares)							64,499
Registered Direct Offering \| Series C warrants
Shares issued (in shares)						66,667
Registered Direct Offering \| Series D warrants
Shares issued (in shares)						66,667
Registered Direct Offering \| Common Stock
Shares issued (in shares)						30,093	57,961
January 2025 Registered Direct Offering
Shares issued (in shares)				123,153
Proceeds from stock issue				$ 2,500,000
Share price (in dollars per share)				$ 20.3
March 2025 Registered Direct Offering
Shares issued (in shares)			107,500
Proceeds from stock issue			$ 1,100,000
Share price (in dollars per share)			$ 8
March 2025 Registered Direct Offering \| Pre-funded warrants
Warrant exercise price (in dollars per share)			$ 7.998
Shares issued (in shares)			29,750
Equity Line of Credit Purchase Agreement
Shares issued (in shares)		72,000
Aggregate value of shares committed for purchase		$ 12,000,000
Proceeds from stock issue		$ 709,140
Share price (in dollars per share)		$ 9.85
Equity Line of Credit Purchase Agreement \| Common Stock
Shares issued (in shares)		72,000
Aggregate value of shares committed for purchase		$ 12,000,000
Common stock, Par value		$ 0.001
Proceeds from stock issue		$ 700,000
Warrant Inducement Agreement
Warrant exercise price (in dollars per share)	$ 12
Proceeds from stock issue	$ 2,700,000
Proceeds from warrant exercises	$ 2,700,000
Warrant Inducement Agreement \| Series A warrants
Warrant exercise price (in dollars per share)	$ 65
Warrant Inducement Agreement \| Series B warrants
Warrant exercise price (in dollars per share)	65
Warrant Inducement Agreement \| Series C warrants
Warrant exercise price (in dollars per share)	65.2
Warrant Inducement Agreement \| Series D warrants
Warrant exercise price (in dollars per share)	$ 65.2
ACX362E
Cash paid									$ 110,174
Future commitment									$ 700,000
Royalty payments to date											$ 200,000
Royalty payments on net sales (as a percent)									4.00%
ACX362E \| Members' Equity, Class B
Granting (in shares)									100,000
Warrant exercise price (in dollars per share)									$ 0.1